Overall, PDXCs recapitulate the resistance to BRAF and MEK inhibitor therapy observed in the patient, and PDXCs from treatment-naive BRAF-mutant melanoma patients showed a marked response to BRAF and MEK inhibitor therapy. This evidence concerns the gene BRAF and melanoma.